Neovacs partners with 3P Biopharmaceuticals to manufacture interferon alpha cytokine

The collaboration follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from AMEGABIOTECH.

This license agreement will allow Neovacs to directly transfer AMEGABIOTECH's technology to the production site of 3P Biopharmaceuticals, which will ensure the manufacture of the IFNα cytokine.

As the only Spanish manufacturer of biological products in the healthcare field, 3P Biopharmaceuticals has a successful track record working with top pharma and biotech companies throughout Europe and the United States.

Neovacs CEO Miguel Sieler said: “This partnership is in line with the recent license agreement signed with AMEGABIOTECH. The completion of these two steps allows us to secure the complete production chain for the manufacture of IFNα, one of the primary raw materials of our most advanced product, IFNα Kinoid.

"In addition, the agreement complements the partnership signed earlier this year with Stellar Biotechnologies, the supplier of the other main component of our vaccine IFNα Kinoid, Keyhole Limpet Hemocyanin (KLH). Within the framework of this partnership, Stellar Biotechnologies holds 30% of Neostell, the production subsidiary of Neovacs.”

3P Biopharmaceuticals business development director Elena Erroba said: “3P Biopharmaceuticals is very happy with this collaboration. It will allow 3P Biopharmaceuticals to contribute to a very innovative therapeutic approach, with our strong competence in the field of manufacturing high quality protein.”